Advertisement
UK markets close in 3 hours 36 minutes

  • FTSE 100

    8,116.92
    +38.06 (+0.47%)
     

  • FTSE 250

    19,816.46
    +214.48 (+1.09%)
     

  • AIM

    755.22
    +2.10 (+0.28%)
     

  • GBP/EUR

    1.1673
    +0.0016 (+0.14%)
     

  • GBP/USD

    1.2513
    +0.0002 (+0.02%)
     

  • Bitcoin GBP

    51,328.30
    +292.76 (+0.57%)
     

  • CMC Crypto 200

    1,384.85
    -11.68 (-0.84%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.04
    +0.47 (+0.56%)
     

  • GOLD FUTURES

    2,357.20
    +14.70 (+0.63%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,051.49
    +134.21 (+0.75%)
     

  • CAC 40

    8,040.67
    +24.02 (+0.30%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Compared to Estimates, Danaher (DHR) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2-min read

Danaher (DHR) reported $7.17 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 6.8%. EPS of $2.36 for the same period compares to $2.76 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $7.03 billion, representing a surprise of +1.97%. The company delivered an EPS surprise of +4.42%, with the consensus EPS estimate being $2.26.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Total Growth - Organic sales (Core): 6% versus -3.1% estimated by four analysts on average.

  • Total sales- Diagnostics: $2.38 billion versus the four-analyst average estimate of $2.26 billion. The reported number represents a year-over-year change of -10.1%.

  • Total sales- Life Sciences: $1.71 billion compared to the $1.70 billion average estimate based on four analysts. The reported number represents a change of -56% year over year.

  • Total sales- Environmental & Applied Solutions: $1.22 billion versus the four-analyst average estimate of $1.42 billion. The reported number represents a year-over-year change of +4.8%.

View all Key Company Metrics for Danaher here>>>

Shares of Danaher have returned +2.6% over the past month versus the Zacks S&P 500 composite's +4.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Danaher Corporation (DHR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research